enGene (ENGNW) Stock Price, News & Analysis

Company Overview

enGene Inc is a clinical-stage biotechnology company developing a proprietary platform for targeted delivery of therapeutic agents using bacterially derived nanocells. The company engineers anucleated bacterial minicells that can be loaded with cytotoxic drugs, nucleic acids or immunomodulators and equipped with targeting ligands to selectively bind and deliver payloads to diseased cells, with the aim of maximizing efficacy while reducing off-target toxicity.

enGene’s pipeline features multiple candidate nanocell formulations in preclinical and early clinical development for the treatment of solid tumors and other indications. By harnessing the unique size, biocompatibility and customizability of its nanocell constructs, the company seeks to address limitations of conventional chemotherapy and biologics, including poor tissue penetration and systemic side effects. Research activities include evaluation of different payloads, surface markers and dosing regimens to optimize therapeutic performance.

Headquartered in Brisbane, Australia, enGene also maintains a presence in North America to support collaborations with clinical research organizations and academic institutions. The company’s leadership team comprises professionals with extensive experience in drug discovery, translational research and pharmaceutical development, guiding the strategic advancement of its targeted delivery technology through regulatory milestones and clinical partnerships.

Key Stats

• Today's Range: $0.68 to $0.72
• 50-Day Range: $0.65 to $1.10
• 52-Week Range: $0.51 to $2.74
• Volume: 2,520 shs
• Average Volume: 8,079 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ENGNW Stock Analysis - Frequently Asked Questions

How have ENGNW shares performed this year?

enGene's stock was trading at $0.8433 at the beginning of 2025. Since then, ENGNW stock has decreased by 15.2% and is now trading at $0.7150.

How do I buy shares of enGene?

Shares of ENGNW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ENGNW
• CIK: 1980845
• Web: www.engene.com
• Phone: 514-332-4888
• Fax: N/A
• Employees: 31
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: N/A
• Beta: N/A